Selvita S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2019-04-05
Share capital
14,684,379.20 PLN
Activity description

Selvita is an integrated service provider specializing in drug discovery and drug development. It offers comprehensive services from target validation to preclinical candidate nomination, supporting small molecules, antibodies, and protein degraders, along with extensive drug development and regulatory support for both small and large molecules. The company adheres to GMP and GLP regulations, ensuring scientific consistency and global compliance throughout the development process.

Registered address
ul. Podole 79, 30-394 Kraków, Poland
Phone
Social media
Electronic delivery address
AE:PL-89395-12011-IFSDT-12

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 10 days early. All were audited by a statutory auditor.

  • 202530/06/2026
  • 202410/07/2025
  • 202328/06/2024
  • 202212/07/2023
  • 202114/07/2022
  • 202029/09/2021
Filed on timeDelayFiling deadline

The statements for 2025 report only zeros (no activity).

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 16.82
-0.46 (-2.66%)
16.6016.8017.0017.2016.8210:0012:0014:0016:00
Open
PLN 17.28
High
PLN 17.30
Low
PLN 16.52
Volume
21.66K
Avg. vol.
36.91K
Market cap
PLN 308.74M
P/E ratio
–
EPS
-PLN 0.11
Shares outstanding
18.36M
52-week
PLN 15.56 – 18.34
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 22.19mUSD -183.95kUSD -821.45k
Q1 2026USD 20.52mUSD -482.44kUSD -1.47m
Q4 2025USD 23.26mUSD 2.11mUSD 1.84m
Q3 2025USD 22.12mUSD 572.58kUSD -235.06k

Results for Q3 2026:Nov 19, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 1.4%
City · Kraków97 / 16,145
Top <1%
Voivodeship · Małopolskie186 / 27,724
Top <1%
Country · Poland2,515 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 91.69mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD 204.17kMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 89.71mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 150.12mMedianUSD 281.58kAverageUSD 8.35m

Public procurement

1 tender recorded as contractor, with a total value of $13,687.

SubjectAmount
459.2024 Selection of a contractor to consult on the content of course syllabi for the Faculty of Chemistry, divided into six lots.
$13,687

Authorized Representatives

Bogusław Stanisław Sieczkowski age 54 – Vice President of the Management Board
Rafał Piotr Chwast age 55 – President of the Management Board
Dariusz Tomasz Kurdas age 48 – Management Board Member
Dawid Patryk Radziszewski age 40 – Management Board Member
Joanna Dominika Wojas age 45 – Attorney-in-fact (joint)

Manner of representation

In the case of a multi-member management board, the company may be represented by two members of the management board acting jointly, or by a member of the management board acting jointly with one of the joint commercial proxies.

Supervisory board

Jacek Andrzej Osowski age 49 – Supervisory Board Member
Wojciech Wit Chabasiewicz age 52 – Supervisory Board Member
Paweł Tadeusz Przewięźlikowski age 54 – Supervisory Board Member
Piotr Romanowski age 57 – Supervisory Board Member
Tadeusz Wesołowski age 75 – Supervisory Board Member

Beneficial owners

Selvita is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Capital group

NameOwnership
Aktywa netto p rzypadające n a Selvita S.A.
74%
Selvita Inc
100%
Selvita Ltd
100%

Bank accounts

Registered as a VAT taxpayer on 2019-08-09.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

6 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Jun 2, 2020Commercial Companies Code notice
Jun 2, 2020Commercial Companies Code notice
Oct 14, 2019Merger registered
Oct 14, 2019Call to creditors
Jul 24, 2019Merger registered

Public aid

19 public aid cases recorded, with a total value of $45,055,001.

PurposeGross amount
Regional investment aid
–
Aid for research and development projects: industrial research
–
Aid for research and development projects: experimental development
–

European Funds

8 projects co-financed from European Funds recorded, with total EU co-financing of $35,260,216.

ProjectEU co-financing
Development of DRUG-PREDICT technology for preclinical prediction of the clinical efficacy of biologically active compounds for colorectal and pancreatic cancer indications, based on translational preclinical in vitro and in vivo models supported by an ML tool, enabling the identification of the best innovative drug candidates and optimal patient groups
$3.5M
Advanced E3Explorer platform for the production of E3 ligase proteins, together with their characterization, as the basis for innovative PROTAC targeted therapies
$2.3M
CART-AI platform for developing advanced immuno-oncology therapies based on modified T lymphocytes using AI – preclinical stage
$2.5M

Regulatory authorisations

AuthorityTypeStatus
Waste generation Active

Competitors

Name
Roche Polska sp. z o.o.
Sciencepharma sp. z o.o.
Narodowe Centrum Badań Jądrowych Research institute
Instytut Matki i Dziecka Research institute
Iqvia Solutions Poland sp. z o.o.
PPD Poland sp. z o.o.
KCR S.A.
Pratia S.A.
Sieć Badawcza Łukasiewicz - Instytut Mikroelektroniki i Fotoniki Research institute
Sieć Badawcza Łukasiewicz - Port Polski Ośrodek Rozwoju Technologii Research institute

Change history

DateEvent
2023-05-31Address change
2020-06-18Share capital increase
2020-02-14Share capital reduction
2019-10-01Share capital increase
2019-10-01Name change

FAQ

Last updated: 2026-10-08